四磨汤与瘅胃散治疗糖尿病性胃轻瘫的疗效

The Curative Effect of Simotang and Gastric Powder on Treatment of Diabetic Gastroparesis

研究四磨汤联合瘅胃散治疗脾虚气滞型糖尿病性胃轻瘫患者胃肠功能障碍的临床效果。本研究选取2013年8月至2015年8月我院接诊的60例脾虚气滞型糖尿病性胃轻瘫患者。按随机数表法分为观察组和对照组,给予对照组采取瘅胃散治疗,观察组在对照组的基础上加用四磨汤治疗,观察两组患者治疗后血糖水平、临床症状及疗效的改善效果。通过相关分析表明治疗后,观察组FPG、2hPG(6.84±1.20,8.85±1.50)mmol/L小于对照组(8.21±1.10,11.03±1.30)mmol/L,HbAlc(7.08±1.25)%小于对照组(8.87±1.30)%差异具有统计学意义(p<0.05);观察组早饱、腹胀、恶心、呕吐、厌食、便秘腹泻交作、舌象改善时间(1.05±0.35,1.03±0.32,0.76±0.14,0.65±0.14,0.80±0.26,0.62±0.15,0.87±0.10)周均小于对照组(1.56±0.32,1.46±0.36,0.92±0.26,0.72±0.22,1.20±0.28,0.87±0.18,10.13±0.29)周差异具有统计学意义(p<0.05);观察组MDA(2.53±0.75)nmol/L小于对照组(3.12±0.80)nmol/L;IL-6(26.28±3.26)pg/mL小于对照组(35.12±3.01)pg/m L;CPR(2.21±0.29)mg/L小于对照组(4.59±1.18)mg/L差异具有统计学意义(p<0.05);观察组临床疗效96.66%(29/30)优于对照组70.00%(21/30)差异具有统计学意义(p<0.05)。研究结果表明,四磨汤联合瘅胃散对改善脾虚气滞型糖尿病性胃轻瘫患者胃肠功能障碍疗效显著,值得临床推广。

Th e objective of this study was to investigate the clinical effect Simotang combined with gastric powder on treating the gastrointestinal dysfunction of diabetic gastroparesis patients with spleen deficiency and qi stagnation. 60 cases of spleen and diabetic gastroparesis patients that accepted in our hospital from August 2013 to August 2015 were selected, who were divided into observation group and control group by random number table. The control group was treated with gastric powder, while the control group was treated with Simotang combined with gastric powder, and the blood sugar levels, clinical symptoms and the improvement of the efficacy of the two groups after treatment were observed. The correlation analysis showed that after treatment, the FPG, 2hPG of the observation group （6.84±1.20） mmol/L, （8.85±1.50） mmol/L） were less than the control group （8.21±1.10） mmol/L, （11.03±1.30） mmol/L, and the HbAlc （7.08±1.25）% of the observation group was also less than the control group （8.87±1.30）%, and the difference was statistically significant （p〈0.05）. The time of early satiety, abdominal distension, nausea, vomiting, anorexia, constipation and diarrhea cross attack, and improvement of tongue image of the observation group （1.05±0.35） week, （1.03 ±0.32） week, （0.76±0.14） week, （0.65 ±0.14） week, （0.80±0.26） week, （0.62±0.15） week, （0.87±0.10） week） were less than the control group （1.56±0.32） week, （1.46±0.36） week, （0.92 ±0.26） week, （0.72±0.22） week, （1.20±0.28） week, （0.87±0.18） week, （10.13±0.29） week）, and the difference were statistically significant （p〈0.05）. Moreover, the MDA of the observation group （2.53±0.75） nmol/L was less than the control group （3.12±0.80） nmol/L. Besides, the IL-6 （26.28±3.26） pg/mL of the observation group was less than the control group （35.12±3.01） pg/mL, and the CPR （2.21±0.29） mg/L was less than the control group （4.59±1.18） mg/L, and the difference was statistically significant （p〈0.05）. The clinical curative effect of the observation group 96.66% （29/30） was better than the control group 70.00% （21/30）, and the difference was statistically significant （p 〈0.05）. Research results indicated that Simotang combined with gastric powder could well improve the gastrointestinal dysfunction patients with spleen deficiency and qi stagnation type diabetic gastroparesis, which was worthy of promotion in clinic.